Clinical trial
Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With…
NCT00227656 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00227656 |
|---|---|
| Title | Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer |
| Official title | Phase II Trial of Capecitabine (Xeloda®) and Pegylated Interferon Alfa-2A(Pegasys®) for Recurrent or Progressive Brain Metastasis From Breast Carcinoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Metastatic Cancer |
| Intervention type | Biological, Drug |
| Interventions | PEG-interferon alfa-2a, Capecitabine |
| Enrollment | 2 |
| Start date | Sep 1, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Sep 28, 2005 |
| Last update posted | Dec 11, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: